iNovacia Has Been Acquired By Kancera AB

iNovacia will continue to support external customers.

During 2010 and 2011, iNovacia has successfully been providing drug discovery services to Kancera, primarily within identification and optimization of novel and competitive lead series in Kancera's preclinical cancer programs. The now completed acquisition of iNovacia's highly regarded and validated organization brings further credibility to Kancera's effort to develop cutting-edge cancer programs with both quality and speed.

iNovacia will continue to work with current and future external customers providing quality lead identification services including e.g. assay development, high-throughput screening (HTS), fragment-based screening (FBS) and medicinal chemistry. Kancera sees the benefit of also in the future make the highly regarded iNovacia screening compound collection and lead identification operations available to external customers in the pharma and biotech industry.

"Working with external customers is rewarding and makes the organization maintain its focus on efficient delivery of high value and continuous operations improvement" says Kancera CEO Dr Thomas Olin.

Kancera brings strong clinical expertise and a cancer program portfolio consisting of PFKFB3 inhibitors for the treatment of solid tumors and ROR-1 inhibitors for the treatment of hematological malignancies. Kancera also develops a unique cancer model laboratory with e.g. a novel surrogate human environment in vivo model. These models, bringing improved predictability and clinical relevance, will be made available through selected partnerships and thereby adding further value to future external customers of iNovacia with an interest in the oncology field.

iNovacia will continue to work with external big pharma and biotech customers across all therapeutic areas and target families.

SOURCE: iNovacia AB